Progenics Pharmaceuticals, Inc. announced earnings results for the fourth quarter ended December 31, 2019. For the fourth quarter, the company announced total revenue was USD 15.126 million compared to USD 3.238 million a year ago. Operating loss was USD 10.715 million compared to USD 14.552 million a year ago. Net loss was USD 11.275 million compared to USD 14.704 million a year ago. Basic loss per share was USD 0.13 compared to USD 0.17 a year ago. For the full year, total revenue was USD 34.986 million compared to USD 15.622 million a year ago. Operating loss was USD 66.159 million compared to USD 66.356 million a year ago. Net loss was USD 68.552 million compared to USD 67.657 million a year ago. Basic loss per share was USD 0.8 compared to USD 0.87 a year ago.